Get in Touch
ERG’s mission is to provide the highest quality clinical trial execution across all clinical research phases to help sponsors.
Providing Sponsors Foundation for Success in Obesity Trials
A Phase 1 study investigating an injectable non-incretin biologic was performed at 2 ERG sites enrolled 38 obese normal healthy individuals.
- Strategically tiered site activation
- Enrolled fully and on time
- Progressed to Phase 2
- Fully Captive ERG site solutions
- Streamlined execution with CRO partner
7 Day
Domiciled Period
5
Outpatient Visits
98 Day
Total Trial Duration
Scope
The study targeted healthy obese subjects (BMI 30-40 kg/m2). This Phase 1 was a formulation bridging study for pharmacokinetic, safety, tolerability, and pharmacodynamic biomarkers. The CRO scope of work included clinical monitoring, project management, medical monitoring, data management, statics, and medical writing.
